about
Electron Transport Disturbances and Neurodegeneration: From Albert Szent-Györgyi's Concept (Szeged) till Novel Approaches to Boost Mitochondrial BioenergeticsA new myelin protein, TPPP/p25, reduced in demyelinated lesions is enriched in cerebrospinal fluid of multiple sclerosisalpha-Tocopherol/lipid ratio in blood is decreased in patients with Leber's hereditary optic neuropathy and asymptomatic carriers of the 11778 mtDNA mutationMice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicityMice lacking alpha-synuclein are resistant to mitochondrial toxinsCognitive functions in ataxia with oculomotor apraxia type 2.High-throughput sequencing revealed a novel SETX mutation in a Hungarian patient with amyotrophic lateral sclerosis.The role of cognitive training in the neurorehabilitation of a patient who survived a lightning strike. A case study.Target identification for stereotactic thalamotomy using diffusion tractography.B7 costimulation and intracellular indoleamine-2,3-dioxygenase (IDO) expression in peripheral blood of healthy pregnant and non-pregnant women.Is the MDS-UPDRS a Good Screening Tool for Detecting Sleep Problems and Daytime Sleepiness in Parkinson's Disease?Novel therapeutic strategies in Parkinson's disease.Language deficits in pre-symptomatic Huntington's disease: evidence from Hungarian.The establishment of tocopherol reference intervals for Hungarian adult population using a validated HPLC method.Targeting the kynurenine pathway-related alterations in Alzheimer's disease: a future therapeutic strategy.Kynurenines in Parkinson's disease: therapeutic perspectives.Mitochondrial disturbances, tryptophan metabolites and neurodegeneration: medicinal chemistry aspects.Manipulating kynurenic acid levels in the brain - on the edge between neuroprotection and cognitive dysfunction.Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease.Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets.The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis.Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Novel AARS2 gene mutation producing leukodystrophy: a case report.Lack of age-related clinical progression in PGC-1α-deficient mice - implications for mitochondrial encephalopathies.Relevance of defensin β-2 and α defensins (HNP1-3) in Alzheimer's disease.Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.The Genetic Link between Parkinson's Disease and the Kynurenine Pathway Is Still Missing.Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease.Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.Transgenic ALS mice show increased vulnerability to the mitochondrial toxins MPTP and 3-nitropropionic acid.Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice.Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.Association of vitamin D receptor gene polymorphisms and Parkinson's disease in Hungarians.Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity.Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease.Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease.Behaviour changes in a transgenic model of Huntington's disease.Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice.Malonate and 3-nitropropionic acid neurotoxicity are reduced in transgenic mice expressing a caspase-1 dominant-negative mutant.Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease.
P50
Q26795417-22D965CD-E91F-47EA-BF8A-0809A7101976Q28237428-E44687BD-6008-419E-84A1-443B687A5A65Q28350335-FC178F8D-EA49-400A-B36B-C40716596767Q28510922-BAE84A7F-5D58-44EF-BCC1-53A60DF933EEQ28511475-35D40045-328F-4A40-9BC0-22767D2A3B58Q30463388-E3ED9D76-12D6-485A-8252-A224AB64A8FFQ33562187-FB243B6D-4BE9-415A-B905-C5C625821668Q34041395-DC56340D-8E7D-4808-B10A-D61616B3D98DQ34125379-5C740FFB-CB12-4262-BE5F-1EA802E3C404Q34169250-7E195204-9409-4F7F-A2A3-8D5ECB0D3E88Q34610885-10405762-5BD5-44E4-9D8B-5B3F43994332Q34612832-519D06EA-620B-4D8B-BEC7-1B4CE090BC90Q35954594-9039426F-2211-4D8C-8B5B-D45C9A667B22Q36275874-F0FA2527-7543-4640-80CF-965C602D80FFQ37858350-F7581F71-5EC2-4145-AFA4-0DF046D09F0BQ37920750-9C7FCD88-494C-4628-A15C-E3F32744D262Q37994780-C3E2F124-64B2-4579-9FDA-CEE16A686D13Q38048907-4C949C26-06C9-442E-8320-90A997D4AB03Q38063779-614A3C4E-C312-44B8-B57E-486966BD0B48Q38199559-42DEDA57-C2D1-4E37-8193-DE247E950B17Q38830945-5AA782C2-A428-4825-B646-96E51A49510AQ38832886-9402495A-2AD4-448A-AD07-57D06C02D46FQ39296742-38BBCCE7-1CB1-42A7-8887-9CE81D3CE715Q39594110-7EDDC308-8366-409C-AC50-D036A43D3258Q39848374-B8C2F7EC-F8BF-42B9-9FD5-16C276EA32C9Q42469255-A98E9198-241B-4E6B-820F-A4868DB65F8AQ43170816-DFABD818-C917-470E-B96C-A28DC8F83C7DQ43237018-0BE63DB1-5576-4B73-A9D2-1F1E2C24EE33Q43288037-48669664-E93A-488B-A05B-28649F7355A0Q43547870-1D1E88A2-A443-4664-9425-9A6D9F4689FAQ44591596-E19DBD11-E3B0-4455-98F0-7557A0C8E502Q44674342-BB9A6F96-0DB3-4FD3-A73E-1F39A05FF388Q44722260-7A588E3E-BCBE-4111-9E3C-B9E8431703ACQ45207540-0FFDC1BE-4D37-4668-AC65-49E2B2A0CE2CQ45289337-FF8ABC9A-2B81-423B-98D7-926B00CE21ACQ45294258-9B2E1041-6478-4128-995C-8B6B90741ED2Q45299942-FE59EE0E-3A0F-47D7-BD3D-3DB385B776D4Q45300316-29BB2105-A525-4209-B30D-0C9D5B406973Q45300831-DD09A06D-BC3F-4D3D-AC2F-6EABC0172C29Q45301079-C64A06A4-DC0A-456A-A8B7-6913449B3F87
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-5389-3266
@en
name
Peter Klivenyi
@ast
Peter Klivenyi
@en
Peter Klivenyi
@es
Peter Klivenyi
@nl
type
label
Peter Klivenyi
@ast
Peter Klivenyi
@en
Peter Klivenyi
@es
Peter Klivenyi
@nl
prefLabel
Peter Klivenyi
@ast
Peter Klivenyi
@en
Peter Klivenyi
@es
Peter Klivenyi
@nl
P106
P1153
6701617098
P2798
P31
P496
0000-0002-5389-3266